“We are a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. We designed our product candidates to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Our lead product candidate, PHX1149, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that we are developing as an oral, once-daily treatment for Type 2 diabetes. Our second product candidate, PHX1766, is a protease inhibitor currently in preclinical development for the treatment of hepatitis C virus, or HCV, infection.

We have an active discovery program focused on enzyme targets, including proteases, kinases and polymerases.”

(Source: Phenomix)


Date Type Amount Investors Valuation
05/01/05 Series B 40M JPMorgan Partners, Delphi Ventures, Baker Brothers Investments, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, GBS Venture Partners, Novartis BioVenture Fund Unknown
03/01/07 Series C 55M CMEA Ventures, GBS Venture Partners, Delphi Ventures, Bay City Capital, Alta Partners, Novartis BioVenture Fund, Sofinnova Ventures, Baker Brothers, JP Morgan Partners Unknown
10/01/08 Series D 75M Forest Laboratories, Inc Unknown


Christopher Burnley (Executive Vice President and Chief Operating Officer)

John Crawford (Chief Financial Officer)

Hans-Peter Guler (Vice President, Clinical Development)

David Campbell (Vice President, Drug Discovery and Preclinical Sciences)

Brian Baker (CEO)

View more details about all 16 people at Phenomix